FibroBiologics, Inc. (FBLG) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US31573L2043
FibroBiologics, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | – | 0.00 USD |
| Gross profit | – | -832,000.00 USD |
| Operating income | -16.65 m USD | -16.65 m USD |
| EBIT | -18.69 m USD | – |
| Net income | -18.65 m USD | -18.65 m USD |
| Diluted EPS – continuing operations | -0.42 USD | – |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About FibroBiologics, Inc.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
More stocks
- NEXGEL, INC. (NXGL)
- Circle Energy, Inc./NV (CRCE)
- CID Holdco, Inc. (DAIC)
- ALTEX INDUSTRIES INC (ALTX)
- Accustem Sciences Inc. (ACUT)
- HeartCore Enterprises, Inc. (HTCR)
- MUSTANG BIO, INC. (MBIO)
- TOFUTTI BRANDS INC (TOFB)
- OMNIQ Corp. (OMQS)
- Propanc Biopharma, Inc. (PPCB)
- Sunshine Biopharma Inc. (SBFM)
- Nexalin Technology, Inc. (NXL)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.